Wealth Enhancement Advisory Services
TVTX icon

Wealth Enhancement Advisory Services’s Travere Therapeutics TVTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Buy
+6,445
New +$286K ﹤0.01% 3003
2026
Q1 		– Sell
-6,261
Closed -$224K – 3867
2025
Q4 		$224K Buy
+6,261
New +$204K ﹤0.01% 3180
2025
Q2 		– Sell
-10,139
Closed -$182K – 3489
2025
Q1 		$182K Buy
+10,139
New +$206K ﹤0.01% 2650

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Wealth Enhancement Advisory Services's TVTX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 6,445 shares worth $365K. The stake represents ﹤0.01% of the portfolio and ranks #3003 among its holdings. This is a return to the name: Wealth Enhancement Advisory Services previously reported a position in TVTX as recently as Q4 2025.

Wealth Enhancement Advisory Services first reported a position in TVTX in Q1 2025 and has held it in 3 quarters since. 110 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 6,445 shares of Travere Therapeutics worth $365K as of Q2 2026.
  • Travere Therapeutics was a new Wealth Enhancement Advisory Services position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3003 holding.
  • Wealth Enhancement Advisory Services first reported a position in Travere Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 110 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.